Heart failure & cardiomyopathies
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Authors' conclusion
In GALACTIC-HF, 10.7% of outpatients with HFrEF had hypermagnesaemia, which was associated with a higher risk of the primary outcome compared with normal magnesium concentrations. Abnormal magnesium levels were not associated with a higher risk of sudden death or ventricular tachyarrhythmias.
Study context
- Population
- Outpatients with HF with reduced ejection fraction (HFrEF) (LVEF ≤ 35%) in GALACTIC-HF (omecamtiv mecarbil vs placebo) with baseline serum magnesium data
- Participants
- 6,147 outpatients
- Comparison
- Hypomagnesaemia and hypermagnesaemia vs normal magnesium
- Hypomagnesaemian = 1,082
- Normal magnesiumn = 4,410reference
- Hypermagnesaemian = 655
- Primary endpoint
- First worsening HF event or CV death
Methodological detailsdouble-blind, multicentre, event-driven
- Double-blind
- Multicentre
- Event-driven
Primary result
As reported in the abstract
Primary composite outcome, incidence rate per 100 person-years
Further findings
Components of primary outcome and all-cause death
- Similar trends to the primary outcome
Sudden death and ventricular tachyarrhythmia
- Did not differ among the three magnesium groups
Death from worsening heart failure (HF)
- Risk highest with hypermagnesaemia
Original publication
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Eur Heart J. Published 31 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →